U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216001) titled 'Role of Omega-DEK in Childhood Apraxia of Speech' on Oct. 10.
Brief Summary: This is a 20-week study for children between 3 and 6 years old with confirmed childhood apraxia of speech (CAS). The study includes a 12-week open-label pilot feasibility study of an investigational drug (Omega-DEK) plus L-carnitine (Carnitor(R)), which is followed by an 8-week randomized, placebo-controlled discontinuation period among the same study participants.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Childhood Apraxia of Speech
Verbal Apraxia
Autism
Intervention:
DRUG: Omega-DEK
Participants take 2 capsules, twice daily...